1. Home
  2. LXEO vs GOSS Comparison

LXEO vs GOSS Comparison

Compare LXEO & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LXEO
  • GOSS
  • Stock Information
  • Founded
  • LXEO 2017
  • GOSS 2015
  • Country
  • LXEO United States
  • GOSS United States
  • Employees
  • LXEO N/A
  • GOSS N/A
  • Industry
  • LXEO
  • GOSS Biotechnology: Pharmaceutical Preparations
  • Sector
  • LXEO
  • GOSS Health Care
  • Exchange
  • LXEO Nasdaq
  • GOSS Nasdaq
  • Market Cap
  • LXEO 252.4M
  • GOSS 212.9M
  • IPO Year
  • LXEO 2023
  • GOSS 2019
  • Fundamental
  • Price
  • LXEO $6.14
  • GOSS $0.81
  • Analyst Decision
  • LXEO Strong Buy
  • GOSS Strong Buy
  • Analyst Count
  • LXEO 5
  • GOSS 5
  • Target Price
  • LXEO $23.80
  • GOSS $9.20
  • AVG Volume (30 Days)
  • LXEO 274.8K
  • GOSS 2.3M
  • Earning Date
  • LXEO 12-31-2024
  • GOSS 11-07-2024
  • Dividend Yield
  • LXEO N/A
  • GOSS N/A
  • EPS Growth
  • LXEO N/A
  • GOSS N/A
  • EPS
  • LXEO N/A
  • GOSS N/A
  • Revenue
  • LXEO N/A
  • GOSS $105,322,000.00
  • Revenue This Year
  • LXEO N/A
  • GOSS N/A
  • Revenue Next Year
  • LXEO N/A
  • GOSS N/A
  • P/E Ratio
  • LXEO N/A
  • GOSS N/A
  • Revenue Growth
  • LXEO N/A
  • GOSS N/A
  • 52 Week Low
  • LXEO $5.77
  • GOSS $0.50
  • 52 Week High
  • LXEO $22.33
  • GOSS $1.60
  • Technical
  • Relative Strength Index (RSI)
  • LXEO 35.77
  • GOSS 49.87
  • Support Level
  • LXEO $6.78
  • GOSS $0.76
  • Resistance Level
  • LXEO $7.40
  • GOSS $0.88
  • Average True Range (ATR)
  • LXEO 0.66
  • GOSS 0.08
  • MACD
  • LXEO -0.13
  • GOSS 0.01
  • Stochastic Oscillator
  • LXEO 1.34
  • GOSS 30.48

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Share on Social Networks: